NCT01132768

The Confirmatory Olmesartan Plaque Regression Study

Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 114 (actual)
• Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Effect of olmesartan medoxomil (20-40 mg) on plaque regression in hypertensive patients with carotid atherosclerosis.

Conditions

• Essential Hypertension
• Carotid Plaque

Interventions

Type	Name	Description
DRUG	Atenolol	Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
DRUG	olmesartan medoxomil	Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2010-05-28
• Last updated: 2018-12-24

Locations

1 site across 1 country: Italy